Get the Stockscreener App
25.62
1.51%
0.38
After Hours:
25.59
-0.03
-0.12%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.62, with a volume of 51.24M.
It is up +1.51% in the last 24 hours and up +9.72% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.24
Open:
$25.24
24h Volume:
51.24M
Relative Volume:
1.05
Market Cap:
$138.15B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
18.57
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
+2.32%
1M Performance:
+9.72%
6M Performance:
-4.62%
1Y Performance:
-8.27%
1-Day Range:
$25.21
$25.96
1-Week Range:
$25.02
$25.96
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.62 | 138.15B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
777.66 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.79 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.64 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
189.77 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
121.68 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707 - geneonline.com
Transcript : Pfizer Inc.Special Call - MarketScreener
Is Pfizer Stock a Buy for Its Massive 7% Dividend Yield? A Trader’s Look - Daily Chhattisgarh News
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others - Fierce Pharma
Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC
Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE) - MSN
Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - Yahoo Finance
Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT - Insider Monkey
Pfizer (PFE) Stock: Analyst Targets Suggest 15% Upside as Company Touts Strong Margins and Dividend - Daily Chhattisgarh News
FDA Denies Pfizer's (PFE) Label Expansion for Talzenna in Prosta - GuruFocus
Pfizer bid to expand Talzenna label faces FDA snub (PFE:NYSE) - Seeking Alpha
Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China - geneonline.com
Pfizer (PFE) Option Activity Shows Mixed Sentiment | PFE Stock N - GuruFocus
Pfizer’s SWOT analysis: stock outlook amid pipeline progress, cost cuts - Investing.com
Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer - MarketScreener
Young minds dive into discovery at Pfizer School of Science Mobile Experience - Yahoo
Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer
BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com
Pfizer (PFE) Stock Shows Strong Rebound with Over 8% Monthly Gain, Halting Longer-Term Slide - Daily Chhattisgarh News
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp - The Globe and Mail
PFIZER INC : UBS remains Neutral - MarketScreener
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ... - Bluefield Daily Telegraph
Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC
4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts - 24/7 Wall St.
Pfizer (PFE) Sees Mixed Options Sentiment Amidst Modest Share In - GuruFocus
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents - marketscreener.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Scraps Bid for Depo-Provera Mass Tort Following Dismissal of Most Phila. Plaintiffs - Law.com
Cantor Fitzgerald Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer says drugmakers met with Trump admin to discuss lowering drug prices - Yahoo Finance
Request for Proposals: Pfizer Independent Research Grant Program 2025 - fundsforNGOs
10 Best Wide Moat Stocks To Buy Now - Insider Monkey
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Globe and Mail
Why China Biotech Is Getting a DeepSeek Moment, Too - Bloomberg.com
Pfizer Settles With Final Defendant in Mektovi Patent Lawsuit - Bloomberg Law News
Pfizer Stock Rallies Over 8% in a Month, but Faces Long-Term Headwinds - Daily Chhattisgarh News
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks - 24/7 Wall St.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - marketscreener.com
Cantor Fitzgerald holds Pfizer stock at Neutral with $24 target By Investing.com - Investing.com India
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE) - Seeking Alpha
No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says - Reuters
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves By Stocktwits - Investing.com India
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):